CAR T-Cell Therapy | Clinical

New Data Solidify Benefit of Loncastuximab Tesirine for Relapsed/Refractory DLBCL

October 01, 2021

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.